Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21799915 | 1.00 | ANPEP (0.42) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL15315436 | 0.96 | ANPEP (0.39) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL16978964 | 0.84 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL21799848 | 0.82 | ANPEP (0.39) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL21800086 | 0.80 | SSTR3 (0.43) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL25825627 | 0.77 | TSHR (0.36) | CA1CA2 | |
| SCHEMBL13866403 | 0.77 | SSTR3 (0.31) | — | |
| SCHEMBL20363524 | 0.76 | ANPEP (0.46) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL15317977 | 0.76 | ANPEP (0.46) | ANPEPERAP2THRBMEN1KMT2A | |
| SCHEMBL22778666 | 0.76 | ANPEP (0.46) | ANPEPERAP2THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871778-B2 | Substituted pyrimidine compounds and their use as SYK inhibitors | GENOSCO (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | Genosco Inc. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | SYK, BTK, LCK | ANPEP 3487/4885ERAP2 3701/4885THRB 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.